GlassScriptPhysician profile
Barry Randall Schneider
NPI 1669490991
$12,533.62
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,010 · 2020: $1,975 · 2021: $2,682 · 2022: $3,036 · 2023: $2,536 · 2024: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,808 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,807.85 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,834.76 | 2019-2024 | Skyrizi, Rinvoq, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,163.12 | 2019-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,228.46 | 2019-2023 | Entyvio, Gattex |
| Ferring Pharmaceuticals INC. | $782.11 | 2019-2023 | Rebyota |
| Janssen Biotech, INC. | $614.13 | 2019-2024 | Stelara, Tremfya |
| Qol Medical, LLC | $588.00 | 2019-2024 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $570.98 | 2019-2023 | Linzess |
| Celgene Corporation | $412.34 | 2021-2023 | Zeposia |
| Genzyme Corporation | $366.81 | 2022-2024 | |
| Pfizer INC. | $349.17 | 2019-2023 | |
| Gilead Sciences, INC. | $334.54 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $261.60 | 2019-2023 | Dificid |
| Nestle Healthcare Nutrition INC. | $220.40 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $196.48 | 2022-2023 | Dupixent |
| Vivus LLC | $196.45 | 2021-2023 | Qsymia, Pancreaze |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Romark Laboratories, Lc | $187.38 | 2020 | |
| Redhill Biopharma INC. | $152.43 | 2021-2023 | Aemcolo, Talicia, Movantik |
| Alnylam Pharmaceuticals INC. | $142.89 | 2021-2023 | Givlaari |
| Janssen Scientific Affairs, LLC | $122.08 | 2019 | |
| Apollo Endosurgery US INC | $121.87 | 2019 | |
| Intercept Pharmaceuticals, INC. | $87.56 | 2021-2022 | |
| Amgen INC. | $80.75 | 2021 | |
| Allergan, INC. | $71.91 | 2019-2020 | |
| Evoke Pharma, INC. | $61.79 | 2020-2021 | |
| Braintree Laboratories, INC. | $55.26 | 2020-2022 | |
| Pharmacosmos Therapeutics INC. | $53.35 | 2021-2022 | |
| Shire North American Group INC | $53.12 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $49.02 | 2022-2024 | Zeposia |
| Intra-Sana Laboratories | $40.73 | 2022 | |
| Shionogi INC | $34.27 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $21.18 | 2022 | |
| Phathom Pharmaceuticals, INC. | $20.23 | 2024 | Voquezna |
| Fresenius Kabi USA, LLC | $17.32 | 2023 | Idacio |
| Boston Scientific Corporation | $14.25 | 2023 | |
| Sandoz INC. | $13.62 | 2023 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.26 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Schneider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.